Michael Thomenius

Michael Thomenius has a diverse work experience in the field of biology and pharmaceuticals. Michael is currently serving as the Vice President of Biology at C4 Therapeutics, Inc. Since joining in October 2021, they have been responsible for overseeing biology-related operations and strategies.

Prior to their current role, Michael held positions at Foghorn Therapeutics, Inc. From April 2019 to February 2021, they served as the Director of Biology, and from February 2021 to November 2021, they worked as the Senior Director of Biology. In these roles, they contributed to the development and execution of the company's biology programs.

Before joining Foghorn Therapeutics, Michael worked at Epizyme from October 2011 to March 2019. During their tenure, they held several positions, including Director, Principal Scientist, Sr. Scientist, and Scientist. In these roles, they conducted scientific research, contributed to project development, and played an important role in various scientific initiatives.

Prior to Epizyme, Michael worked briefly at Eutropics Pharmaceuticals in 2011 as a Scientist.

Michael's earlier work includes a post-doctoral role at Duke University Medical Center from May 2004 to September 2009, where they worked as a Post-Doctoral Fellow. During this time, they made significant contributions in the field of cell death regulation and mitochondrial morphology.

In summary, Michael Thomenius has a strong background in biology and pharmaceuticals, with extensive experience in various leadership and scientific roles.

Michael Thomenius obtained a Bachelor of Arts degree in Biochemistry from The College of Wooster, where they studied from 1995 to 1999. Michael then pursued further education at Case Western Reserve University School of Medicine, earning a Ph.D. in Pharmacology, which they completed between 1999 and 2004. Following this, Michael engaged in Post-Doctoral Studies in Oncology and Cancer Biology at Duke University from 2005 to 2010.